Advanced

Contribution of structural biology to clinically validated target proteins

Mori, Masumi; Ogawa, Naoko; Tanikawa, Kunihiro; Dodo, Sanae; Shibayama, Sotaro LU ; Yokoyama, Shigeyuki and Tanaka, Akiko (2008) In Drug Discovery Today 13(11-12). p.469-472
Abstract

We identified six groups of diseases expected to cause serious future health issues on the basis of a WHO report. Approved drugs for these diseases were associated with 409 target proteins; however, the percentage of selected proteins with full-length structural information deposited in the Protein Data Bank (PDB) was only 9.8%. The reason for the low percentage may be as a result of a disproportionate number of intractable proteins with multiple transmembrane regions and variable, or undefined glycosylation patterns, which impede protein preparation and crystallization, in such druggable proteins. We stress the importance of structural analysis of proteins, especially approved-drug target proteins, and the development of new methods to... (More)

We identified six groups of diseases expected to cause serious future health issues on the basis of a WHO report. Approved drugs for these diseases were associated with 409 target proteins; however, the percentage of selected proteins with full-length structural information deposited in the Protein Data Bank (PDB) was only 9.8%. The reason for the low percentage may be as a result of a disproportionate number of intractable proteins with multiple transmembrane regions and variable, or undefined glycosylation patterns, which impede protein preparation and crystallization, in such druggable proteins. We stress the importance of structural analysis of proteins, especially approved-drug target proteins, and the development of new methods to enable structural analyses of presently intractable proteins. In addition, we present an overview of large structural biology projects.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
in
Drug Discovery Today
volume
13
issue
11-12
pages
4 pages
publisher
Elsevier
external identifiers
  • scopus:44649193825
ISSN
1359-6446
DOI
10.1016/j.drudis.2008.03.008
language
English
LU publication?
no
id
10c32959-bc4f-4c8d-bb81-ddf742ee84d9
date added to LUP
2017-04-13 17:48:45
date last changed
2017-04-19 09:30:48
@article{10c32959-bc4f-4c8d-bb81-ddf742ee84d9,
  abstract     = {<p>We identified six groups of diseases expected to cause serious future health issues on the basis of a WHO report. Approved drugs for these diseases were associated with 409 target proteins; however, the percentage of selected proteins with full-length structural information deposited in the Protein Data Bank (PDB) was only 9.8%. The reason for the low percentage may be as a result of a disproportionate number of intractable proteins with multiple transmembrane regions and variable, or undefined glycosylation patterns, which impede protein preparation and crystallization, in such druggable proteins. We stress the importance of structural analysis of proteins, especially approved-drug target proteins, and the development of new methods to enable structural analyses of presently intractable proteins. In addition, we present an overview of large structural biology projects.</p>},
  author       = {Mori, Masumi and Ogawa, Naoko and Tanikawa, Kunihiro and Dodo, Sanae and Shibayama, Sotaro and Yokoyama, Shigeyuki and Tanaka, Akiko},
  issn         = {1359-6446},
  language     = {eng},
  number       = {11-12},
  pages        = {469--472},
  publisher    = {Elsevier},
  series       = {Drug Discovery Today},
  title        = {Contribution of structural biology to clinically validated target proteins},
  url          = {http://dx.doi.org/10.1016/j.drudis.2008.03.008},
  volume       = {13},
  year         = {2008},
}